EP Patent

EP3184513A1 — Crystalline and amorphous forms of olaparib

Assigned to Olon SpA · Expires 2017-06-28 · 9y expired

What this patent protects

Disclosed are a novel crystalline form and an amorphous form of Olaparib, and the process for their preparation.

USPTO Abstract

Disclosed are a novel crystalline form and an amorphous form of Olaparib, and the process for their preparation.

Drugs covered by this patent

Patent Metadata

Patent number
EP3184513A1
Jurisdiction
EP
Classification
—
Expires
2017-06-28
Drug substance claim
No
Drug product claim
No
Assignee
Olon SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.